Dual clk/cdk1 inhibitors for cancer treatment
AssigneeSRI International
InventorsThomas R. Webb, Jaehyeon Park, Chandraiah Lagisetti
Life of this patent
Estimating the term…
Abstract
The disclosure generally relates to substituted purine analogs that are dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases. These compounds may be useful in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Claims21
1-20. (canceled)
A compound having a structure represented by a formula selected from:
- wherein n is selected from 1 and 2;
- wherein each of Q1 and Q2 is independently selected from N and CH;
- wherein R1 is selected from —OH, —NHR4, —(C1-C4 alkyl)OH, and —(C1-C4 alkyl)NHR4;
- wherein R4, when present, is selected from hydrogen and C1-C4 alkyl;
- wherein each occurrence of each of R2a, R2b, R2c, R2d, R2e, and R2f is independently selected from hydrogen and C1-C8 alkyl;
- wherein R3 is selected from ethyl and isopropyl;
- and
- wherein Ar1 is selected from monocyclic aryl, 6-membered heteroaryl, and bicyclic heteroaryl, and is substituted with 0-4 groups independently selected from halogen, —OH, —NH2, —CN, —NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —NHC(O)(C1-C4 alkyl), C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,
- or a pharmaceutically acceptable derivative thereof.
A method for treating a disorder having an aberrant germ-like mutation in a subject, the method comprising the step of administering to the subject an effective amount of at least one compound that inhibits CLK2 and/or CDK1.
Dependencies are inferred from the claim text.